Literature DB >> 11040073

Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins.

A Achiron1, F Mor, R Margalit, I R Cohen, O Lider, S Miron.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats either by active immunization with myelin basic protein (MBP) or by adoptive transfer using anti-MBP specific CD4(+)T cells. Treatment with human polyclonal immunoglobulins (IgG) effectively suppressed active EAE. Time-dependent experiments demonstrated that the effect of IgG was manifested only when treatment was given immediately after immunization; administration from day 7 after disease induction did not suppress the disease. In the adoptive transfer model of EAE, IgG had no effect in vivo. However, pretreatment in vitro of the antigen-specific T-cells with IgG inhibited their ability to mediate adoptive EAE, as it did in active EAE. Similarly, in vitro IgG pretreatment of the antigen-specific T-cells suppressed the proliferative response to MBP. Fluorescent Activated Cell Sorter (FACS) analysis demonstrated the binding of IgG to activated T-cell lines that was inhibited by soluble Fc molecules. The differential effects of IgG on active EAE and on the adoptive transfer of EAE suggest that IgG in vivo can suppress disease by acting during the early phase of the immune response which involves naive T cells. The inhibition of T-cell proliferation and adoptive transfer of EAE by incubation of T cells in vitro appears to require higher concentrations of IgG than those obtained in vivo. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040073     DOI: 10.1006/jaut.2000.0433

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions.

Authors:  Signe Humle Jorgensen; Nicolas Storm; Poul Erik Hyldgaard Jensen; Henning Laursen; Per Soelberg Sorensen
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

3.  Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.

Authors:  Anat Achiron; Irena Kishner; Mark Dolev; Yael Stern; Mordechai Dulitzky; Eyal Schiff; Reuven Achiron
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

4.  Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

Authors:  J L McQualter; R Darwiche; C Ewing; M Onuki; T W Kay; J A Hamilton; H H Reid; C C Bernard
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

5.  High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia.

Authors:  Erika K Fenner; Juri Boguniewicz; Rebecca M Tucker; Ronald J Sokol; Cara L Mack
Journal:  Pediatr Res       Date:  2014-04-11       Impact factor: 3.756

6.  Combined Treatment with Zinc Aspartate and Intravenous Immunoglobulins (IVIGs) Ameliorates Experimental Autoimmune Encephalomyelitis (EAE).

Authors:  Diana Straubel; Anja Thielitz; Annegret Reinhold; Kurt Grüngreiff; Dirk Reinhold
Journal:  J Immunol Res       Date:  2018-09-26       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.